CRNX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-1.363

+54.86%

-1.413

+35.82%

-1.407

+14.43%

Estimates Revision

The market is revising Downward the revenue expectations for Crinetics Pharmaceuticals, Inc. (CRNX) for FY2025, with the revenue forecasts being adjusted by -5.23% over the past three months. During the same period, the stock price has changed by 16.35%.

Revenue Estimates for FY2025

Revise Downward

-5.23%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.98%

In Past 3 Month

Stock Price

Go Up

+16.35%

In Past 3 Month

15 Analyst Rating

Wall Street analysts forecast CRNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRNX is 80.00 USD with a low forecast of 45.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

45.00

Averages

80.00

High

108.00

Current: 0.000

Low

45.00

Averages

80.00

High

108.00

Citizens

Jonathan Wolleben

Outperform

downgrade

$108 -> $105

2026-01-08

New

Reason

Citizens

Jonathan Wolleben

Price Target

$108 -> $105

2026-01-08

New

downgrade

Outperform

Reason

Citizens analyst Jonathan Wolleben lowered the firm's price target on Crinetics to $105 from $108 and keeps an Outperform rating on the shares. An initial survey of U.S. endocrinologists indicates a positive early launch experience for Palsonify, supporting the previously announced Q1 top-line beat and suggesting adoption and performance are tracking ahead of expectations, the analyst tells investors in a research note The launch is expected to continue outperforming through 2026, with sales projected above consensus and momentum supported by ongoing pipeline execution and upcoming clinical milestones, the firm says.

RBC Capital

Brian Abrahams

Outperform

maintain

$1.1B

2026-01-05

New

Reason

RBC Capital

Brian Abrahams

Price Target

$1.1B

2026-01-05

New

maintain

Outperform

Reason

RBC Capital analyst Brian Abrahams notes that Neurocrine's (NBIX) CAH competitor Crinetics (CRNX) reported new phase II data from an additional cohort that were allowed to have their GC dose reduced on physician discretion. The data looked very supportive of their drug's ability to rapidly lower A4 levels while enabling GC dose reduction, highlighting a potential competitor that could reach the CAH market within the next few years. However, the firm believes comparing the dataset to Neurocrine's phase III study data is limited, primarily due to the differences in patient population. Overall, RBC notes that while competitor data reaffirms as potential emerging player in the space, this was already well known, patient stickiness may shield Crenessity from future competition, and even with conservative estimates, the firm believes allow for out-year competition for new patient starts, it sees Crenessity contributing $1.1B to Neurocrine's revenue stream in the U.S. market alone. RBC would be a buyer of Outperform-rated Neurocrine on weakness.

Evercore ISI

Outperform

maintain

$80 -> $90

2026-01-05

New

Reason

Evercore ISI

Price Target

$80 -> $90

2026-01-05

New

maintain

Outperform

Reason

Evercore ISI raised the firm's price target on Crinetics to $90 from $80 and keeps an Outperform rating on the shares following what the firm views as "very strong updates" on atumelnant in CAH and the Palsonify launch in acromegaly. The firm believes the atumelnant update will be "much more impactful" for the stock today as it contends that Crinetics "again looks to comfortably have 2 blockbuster," high odds of success products and more in earlier development.

JonesResearch

Buy

maintain

$85 -> $97

2026-01-05

New

Reason

JonesResearch

Price Target

$85 -> $97

2026-01-05

New

maintain

Buy

Reason

JonesResearch raised the firm's price target on Crinetics to $97 from $85 and keeps a Buy rating on the shares after the company pre-announced Palsonify Q4 revenue and Phase 2 TouCAHn cohort 4 atumelnant data in congenital adrenal hyperplasia. The firm says both results exceeded its expectations. Atumelnant "looks highly competitive" in CAH, preserving "impressive" A4 reductions of 67% during GC taper, the analyst tells investors in a research note. Jones increased Crinetics' probability of success in CAH to 65% from 45%.

Goldman Sachs

Neutral

maintain

$40 -> $45

2025-11-10

Reason

Goldman Sachs

Price Target

$40 -> $45

2025-11-10

maintain

Neutral

Reason

Goldman Sachs raised the firm's price target on Crinetics to $45 from $40 and keeps a Neutral rating on the shares.

Citizens JMP

Jonathan Wolleben

Outperform

downgrade

$143 -> $108

2025-11-07

Reason

Citizens JMP

Jonathan Wolleben

Price Target

$143 -> $108

2025-11-07

downgrade

Outperform

Reason

Citizens JMP analyst Jonathan Wolleben lowered the firm's price target on Crinetics to $108 from $143 and keeps an Outperform rating on the shares. Crinetics has hit the ground running following Palsonify's approval in late September, with the first revenue coming in January, which will help set expectations for the launch curve, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Crinetics Pharmaceuticals Inc (CRNX.O) is -8.36, compared to its 5-year average forward P/E of -8.13. For a more detailed relative valuation and DCF analysis to assess Crinetics Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.13

Current PE

-8.36

Overvalued PE

-5.30

Undervalued PE

-10.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.54

Current EV/EBITDA

-7.04

Overvalued EV/EBITDA

-2.60

Undervalued EV/EBITDA

-8.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

943.23

Current PS

129.59

Overvalued PS

2196.54

Undervalued PS

-310.08

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 448.61% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CRNX News & Events

Events Timeline

No data

News

8.5

01-07Globenewswire

PinnedCrinetics Prices 7.62M Share Offering at $45.95, Raising $350M

9.0

01-05Benzinga

Crinetics Pharmaceuticals Reports Significant Results in CAH Study with Atumelnant

9.0

01-05NASDAQ.COM

Crinetics Pharmaceuticals Updates on Atumelnant Phase 2 Trial Results and PALSONIFY Commercialization

People Also Watch

Frequently Asked Questions

What is Crinetics Pharmaceuticals Inc (CRNX) stock price today?

The current price of CRNX is 53.24 USD — it has decreased -0.19 % in the last trading day.

What is Crinetics Pharmaceuticals Inc (CRNX)'s business?

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

What is the price predicton of CRNX Stock?

What is Crinetics Pharmaceuticals Inc (CRNX)'s revenue for the last quarter?

Crinetics Pharmaceuticals Inc revenue for the last quarter amounts to 143.00K USD, decreased % YoY.

What is Crinetics Pharmaceuticals Inc (CRNX)'s earnings per share (EPS) for the last quarter?

Crinetics Pharmaceuticals Inc. EPS for the last quarter amounts to -1.38 USD, increased 43.75 % YoY.

What changes have occurred in the market's expectations for Crinetics Pharmaceuticals Inc (CRNX)'s fundamentals?

How many employees does Crinetics Pharmaceuticals Inc (CRNX). have?

Crinetics Pharmaceuticals Inc (CRNX) has 437 emplpoyees as of January 09 2026.

What is Crinetics Pharmaceuticals Inc (CRNX) market cap?

Today CRNX has the market capitalization of 5.05B USD.